Join thousands of your peers in WCG’s weekly online panels, where clinical trial and public health experts provide the latest insights on COVID-19 and discuss the biggest questions and topics you submit.
Monitor the progress of clinical trials for COVID-19 treatments and vaccines, leveraging data from the WCG Knowledge Base™.
The WCG Trial Insights series brings you weekly insights on trial activity throughout the COVID-19 crisis, based on the extensive services we provide to life science clients and supported by our proprietary and powerful WCG Knowledge Base™.
Need help interpreting critical data to navigate the impact of COVID-19 on trials and sites? We leverage insights and benchmark data from the WCG Knowledge Base to guide best practices for trial performance during this unprecedented time.
More than 1,450 COVID-19 trials have been started in 2020, as the global number of COVID-19 cases reported tops 5.5 million. Of the 139 countries being tracked, 60% have more new cases reported in the last 5 days than in the prior 6-10 days… and those are just for the countries reporting case counts.
WCG is tracking more than 1,400 sites in 29 countries to understand how quickly total trial enrollment is being affected during this pandemic. 23% of sites are now open to enrollment of new participants – another 2 percentage point increase in the past week.
News provided by WCG FDAnews and WCG CenterWatch
Researchers Study Cardiovascular Drugs for COVID-19 Patients
Several common cardiovascular drugs are being studied as potential COVID-19 treatments, with early findings suggesting they pose no increased risks for patients taking them regularly.
Administration Targets Five Vaccine Candidates Under Operation Warp Speed
The Trump administration has reportedly selected five COVID-19 vaccine candidates from a list of 14 to be evaluated under Operation Warp Speed. The five frontrunners are being developed by Moderna, Johnson & Johnson, AstraZeneca, Merck and Pfizer.
Hydroxychloroquine Ineffective for Preventing COVID-19, U of M Study Finds
The University of Minnesota has published results from its COVID-19 hydroxychloroquine trial that show the anti-malaria drug is ineffective at preventing coronavirus infection, echoing negative results from other recent studies.
Leading Medical Journals Question Data From COVID-19 Studies
Two respected medical journals have raised questions about the reliability of data provided by a controversial data analytics company in two different trials done for two COVID-19 treatments.
UK Researchers Test Ibuprofen Formulation as COVID-19 Treatment
Researchers in the UK are launching a clinical trial to test a unique formulation of ibuprofen for treatment of severe acute respiratory distress syndrome (ARDS) in COVID-19 patients.
Novavax Partners With AGC Biologics to Manufacture COVID-19 Vaccine Component
AGC Biologics will scale up production of the adjuvant to help increase Novavax’s capacity to deliver vaccine doses this year.
UK Halts Sales of Fingerprick COVID-19 Antibody Tests
Purchasers who received an antibody test result should not consider the result to be reliable, the agency said.
Drugmakers Report Zoloft Shortage Amid COVID-19
Makers of Zoloft (sertraline hydrochloride) and its generic versions are reporting shortages linked to increased demand during the pandemic coupled with supply chain issues caused by the impact of COVID-19 on manufacturers of active pharmaceutical ingredients (APIs).
Lawmakers Outraged Over Ineffectiveness of FDA’s Foreign Inspections Program
Federal lawmakers yesterday criticized the effectiveness of the FDA’s foreign inspections program, expressing outrage that the controversial anti-malaria drug hydroxychloroquine, which has been used to combat COVID-19, came from foreign plants that have never been inspected.
Hahn Predicts Permanent Changes at FDA Because of COVID-19
The FDA’s changes in response to the COVID-19 outbreak will lead to permanent improvements at the agency, predicts FDA Commissioner Stephen Hahn.
BerGenBio Doses First COVID-19 Patient With Bemcentinib in UK ACCORD Initiative
BerGenBio has announced that the first COVID-19 patient was dosed with bemcentinib in a phase 2 trial to evaluate the drug as a potential treatment.
Celltrion’s COVID-19 Antiviral Shows Positive Results in Pre-Clinical Studies
The company plans to begin human clinical trials next month.
As we navigate COVID-19 together, our clinical trial experts are engaged to address the biggest questions. To submit a topic or question, use the form at the bottom of the page.
Please note: protocol-specific questions for studies under the oversight of a WCG IRB should be submitted through your IRB contact person, not through this form.
Disclaimer: All information available on this site is intended for your general knowledge and is not for the purpose of providing regulatory advice, medical advice, or a substitute for institutional review board review. You should not use this information to determine compliance with any applicable laws or regulations governing institutional review boards and human subjects research.